Pre-Commercial Value Assessment of a Nuclear Medicine Pair to Diagnose and Treat Neuroendocrine Tumors (NET)

When our client, a leading radiopharmaceutical company, needed support to understand the commercial opportunity represented by a Phase III radiopharmaceutical and its diagnostic radiotracer companion, Alira Health stepped in to run a comprehensive analysis.

Read on to learn how our team analyzed the market, assessed value assets, and helped our client move forward with confidence.

For more information, or for a pdf copy of this infographic, contact Piergiulio Lauriano.